These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks identifies IDEXX Laboratories and Iovance Biotherapeutics as potential earnings-beat candidates ahead of their November 2 and November 5, 2026 reports. IDEXX has a +0.59% Earnings ESP, with a $3.73 per-share Most Accurate Estimate versus $3.71 consensus; Iovance has a +22.22% ESP, with an estimate of -$0.07 versus -$0.09 consensus. The article presents positive ESPs as indicators of possible beats, not reported results.

Analysis

Treat the estimate signal as a prompt to investigate, not an earnings thesis. For IDEXX Laboratories (IDXX), the revision edge is small: a modest EPS beat could be outweighed by guidance on organic growth, veterinary-clinic demand, or margins. The market may care more about whether recurring diagnostic demand and instrument placements remain healthy than about a few cents of quarterly EPS. A beat without stable forward indicators could therefore produce little upside—or a sell-the-news response.

Iovance Biotherapeutics (IOVA) is a different, higher-variance setup. A large percentage ESP against a loss-making estimate can reflect a small denominator; it says little about commercial execution, treatment volumes, manufacturing capacity, or cash consumption. A nominal EPS beat is not equivalent to evidence that the business is approaching sustainable economics. The read-through to other cell-therapy companies is limited unless the report clarifies broader operational constraints.

The article’s historical hit rate and return figure are vendor backtest claims, not independently verified evidence of positive post-earnings returns. Beat probability and stock reaction are separate: guidance, quality of revenue, and expectations embedded in the price determine the latter. Near-term risk is event volatility; over 1–3 months, estimate revisions and management commentary matter more. The structural question over 6–18 months is whether operating performance supports durable growth (IDXX) or improved commercial economics (IOVA).

Key Decisions for Investors

• Do not buy either name solely on the ESP statistic. Before the reports, verify estimate dispersion, the size and timing of revisions, and each stock’s implied earnings move; without that, the signal is not enough to establish attractive risk/reward.
• IDXX: keep as a watch, with a conditional long only if the report supports durable organic growth and forward demand rather than just an EPS beat. Falsify the thesis if guidance or relevant demand indicators weaken; avoid chasing a pre-report move unsupported by estimate revisions.
• IOVA: avoid treating the percentage ESP as a standalone bullish catalyst. Focus on commercial execution, manufacturing throughput, and cash use; consider a defined-risk event position only if the expected move and option pricing offer favorable asymmetry. A beat without improving those indicators does not validate the bull case.
• For both names, reassess after guidance rather than trading the headline EPS result. A positive surprise followed by weaker forward commentary is a potential sell-the-news signal; sustained upward revisions would be the stronger confirmation.